GoodRx Holdings, Inc. Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $194.8 million

Full-Year 2025 Revenue: $796.9 million, up 1% year-over-year

Adjusted EBITDA: Q4 at $65 million; Full-Year at $270.5 million, representing 4% growth over 2024

Prescription Transactions Revenue: Declined 6% year-over-year to $544 million, impacted by Rite Aid bankruptcy and lower volume from an Integrated Savings Program partner.

Subscription Revenue: Decreased 3% year-over-year to $83.8 million, with early adoption of condition-specific subscriptions noted.

Pharma Direct Revenue: Increased 41% year-over-year to $151.4 million, driven by partnerships and consumer direct pricing.

Cash Position: Ended 2025 with $261.8 million in cash and $80 million in unused credit capacity.

2Strategic Updates and Business Highlights

Pharma Manufacturer Solutions: Rebranded to GoodRx Pharma Direct, focusing on direct-to-consumer strategies and partnerships with pharmaceutical manufacturers.

Consumer Engagement: Expanded direct-to-consumer affordability programs and condition-specific subscriptions, particularly in weight loss, erectile dysfunction, and hair loss.

Retail Partnerships: Strengthened relationships with retail pharmacies, achieving direct contracts with 9 of the top 10 pharmacies, leading to an 83% increase in order volume quarter-over-quarter.

Employer Direct Offering: Launched to help employers provide integrated cash pricing for medications not covered by insurance.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $750 million and $780 million, reflecting strategic investments in Pharma Direct and subscriptions.

Adjusted EBITDA Guidance: Projected to be at least $230 million.

Pharma Direct Revenue Growth: Anticipated to grow at least 30% year-over-year in 2026.

Subscription Growth: Expected to see significant contributions from condition-specific subscriptions, particularly weight loss, as adoption increases.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Monthly active consumers fell 14% in 2025, although stabilization is expected in 2026.

Pressure on Prescription Transactions Revenue: Anticipated continued pressure due to lower fees negotiated with partners and the impact of previous high-revenue partners like Rite Aid not recurring.

Market Dynamics: Increased competition in the weight loss sector and evolving pharmacy economics may pose challenges.

Unit Economics: Adjustments to unit economics are being made to ensure long-term stability, which may affect near-term profitability.

5Notable Q&A Insights

Revenue Guidance Clarification: Management explained the decline in prescription transaction revenue is due to the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct.

Pharma Budgets: There is a positive trend of pharmaceutical manufacturers pulling forward budgets, indicating a healthy spending environment for direct-to-consumer programs.

Consumer Engagement: The company emphasized the importance of engaging consumers directly, particularly as they seek competitive pricing for medications like GLP-1s.

Marketing Strategy: GoodRx is focusing on optimizing marketing spend towards high-return opportunities, particularly in new subscription offerings.

Long-term Strategy: Management reiterated that while the core Rx Marketplace remains foundational, the evolution towards Pharma Direct and Employer Direct is crucial for future growth and stability. Overall, GoodRx is navigating a challenging environment with strategic pivots aimed at enhancing its value proposition in the evolving healthcare landscape, despite facing headwinds in certain revenue streams.